A Model of the Cost Effectiveness of Infliximab for the Treatment of Severely Active Ulcerative Colitis, in Children and Adolescents Aged 6 to 17 Years, Who Have Had an Inadequate Response to Conventional Therapy
Nov 1, 2013, 00:00 AM
10.1016/j.jval.2013.08.1501
https://www.valueinhealthjournal.com/article/S1098-3015(13)03406-2/fulltext
Section Title :
Disease-Specific Studies
Section Order :
1348
First Page :
A565
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)03406-2&doi=10.1016/j.jval.2013.08.1501